Compare MTH & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTH | CRNX |
|---|---|---|
| Founded | 1985 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.9B |
| IPO Year | 1997 | 2018 |
| Metric | MTH | CRNX |
|---|---|---|
| Price | $74.77 | $34.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $77.63 | $76.75 |
| AVG Volume (30 Days) | 729.8K | ★ 884.6K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | N/A | ★ $1,039,000.00 |
| Revenue This Year | N/A | $720.10 |
| Revenue Next Year | $9.81 | $184.67 |
| P/E Ratio | $89.74 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $58.03 | $25.83 |
| 52 Week High | $84.54 | $57.99 |
| Indicator | MTH | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 69.99 | 47.34 |
| Support Level | $64.44 | $33.15 |
| Resistance Level | $75.43 | $37.23 |
| Average True Range (ATR) | 1.89 | 1.42 |
| MACD | 0.93 | 0.07 |
| Stochastic Oscillator | 96.65 | 52.19 |
Meritage Homes Corp is engaged as a designer and builder of single-family attached and detached homes. It has operations in three regions: West, Central, and East, comprising twelve states: Arizona, California, Colorado, Utah, Tennessee, Texas, Alabama, Florida, Georgia, Mississippi, North Carolina, and South Carolina. The company operates with two principal business segments: homebuilding and financial services. The homebuilding segments are engaged in the business of acquiring and developing land, constructing homes, marketing and selling those homes, and providing warranty and customer services, and the financial services segment offers title and escrow, mortgage, and insurance services. The company generates key revenue from the Homebuilding segment.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.